RxElite Holdings, Inc. develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs), and transdermal patch products.

Sevoflurane
(Sojourn™)

Visit our site www.rxelitesevo.com

Current Stock Quote: Last Trade : 0.27 Trade Time : May 15 Change : .00 (.00%) Prev Close : 0.27 Volume : 0 view chart

News

Straight Talk with Bram Solloway, 31 March 2008, AlphaTrade Video

AlphaTrade Video Interview with RxElite President and CEO

April 21, 2008: RxElite Announces 7 Year Agency Agreement With ACIC Europe Limited to Market Its FineTech Pharmaceuticals Product Line in Europe and Latin America
RxElite announced today it has granted ACIC Europe Limited the exclusive right to represent selected high value Active Pharmaceutical Ingredients (API) produced by its wholly owned subsidiary FineTech Pharmaceuticals, in Europe and Latin America.

April 11, 2008: RxElite Announces Preferred Contract Status Awarded by National Surgical Hospitals for Their Anesthetic Gas Products
RxElite is pleased to announce the contract award from National Surgical Hospitals, for their anesthetic gas products. RxElite was awarded a preferred contract listing for all classes of trade for Sojournª(Sevoflurane) and Terrellª(Isoflurane). Sevoflurane is most commonly used anesthetic gas in the U.S and Isoflurane continues to hold share in the anesthetic gas market.

April 10, 2008: RxElite Announces Preferred Contract Status Awarded for Their Anesthetic Gas Products by Nueterra Healthcare

April 9, 2008: RxElite, Inc. Refiles Registration Statement: Ability to Sell Under Prospectus Reinstated

March 20, 2008: RxElite Awarded Anesthetic Gases Multi-Source Contract by Premier Inc., a Purchasing Network for more than 1,500 U.S. Hospitals and 49,000 Other Healthcare Sites
RxElite today announced the signing of a multi-source contract award with Premier, Inc. for the sale of RxEliteÕs anesthetic gas products, Sevoflurane andIsoflurane. RxElite was awarded this multi-source contract listing for all classes of trade and the companyÕs anesthetic gas products are immediately available to all Premier members..

March 18, 2008: RxElite Notice of Annual Financials Earnings Call
RxElite today announced it will discuss its 2007 year-end financial results in a conference call on Thursday, March 20, 2008, at 11:00 a.m. EST.

March 10, 2008: RxElite Filling Critical Requirement for Strategic Partners in Asia, Europe, and Australia
RxElite announced today that its recent acquisition of the assets of FineTech Laboratories, Ltd. is complete and that the new entity will operate as a wholly owned subsidiary of RxElite under the name FineTech Pharmaceutical, Ltd.

January 22, 2008: RxElite Appoints Rick Schindewolf Vice President for Business Development
RxElite announced today that it has appointed Rick Schindewolf as its Senior Vice President for Business Development. Mr. Schindewolf was formerly a vice president with Cardinal Health, where he helped develop the international business development program for blow-fill-seal and sterile products sales.

January 16, 2008: RxElite Appoints Shannon Stith as VP Finance
RxElite announced today that Shannon M. Stith has joined the company as Vice President of Finance and Principal Financial Officer. Mrs. Stith joins RxElite from her current position as the Vice President and Chief Financial Officer at PCS Edventures!.com, Inc.

January 11, 2008: RxElite Announces Acquisition of Assets of FineTech Laboratories
RxElite, Inc. announces today its acquisition of the business and assets of FineTech Laboratories Ltd. (FineTech), located in Haifa, Israel, for $6.2 million in cash and 18,632,383 shares of RxElite common stock. Combining the ability to develop and manufacture complex active pharmaceutical ingredients with RxElite's robust generic manufacturing and distribution capability is a major step for RxElite

January 7, 2008: /CORRECTION//- RxElite Temporarily Suspends Sales Under Its Registration Statement
RxElite, Inc. announced today that as permitted under the registration rights agreement, it has voluntarily instructed all named selling stockholders to cease using the company's Registration Statement on Form SB-2 (File No. 333-146641) and January 3, 2008 prospectus until further advised.

January 4, 2008: RxElite Registration Statement Suspended
RxElite, Inc. (OTC Bulletin Board: RXEI - News), a developer, manufacturer, and marketer of specialty generic prescription drug products, announced today the suspension of their registration statement covering the resale of 53,747,555 shares

January 3, 2008: RxElite Registration Statement Declared Effective by Securities and Exchange Commission
A registration statement covering the resale of 53,747,555 shares by selling stockholders was declared effective by the Securities and Exchange Commission on January 2, 2008 the company announced.

January 3, 2008: RxElite Completes Senior Secured Note Financing
RxElite has secured $10.5 million of financing from an institutional investor through this issuance of common stock, a senior secured convertible note and common stock purchase warrants the company announced today.

November 26, 2007: RxElite Announces Groundbreaking of New Corporate Facility
RxElite will host a groundbreaking ceremony on December 12, 2007 at the worksite of their new corporate facility in Nampa, Idaho. RS Hosac, Inc. is the developer for the site and is working with RxElite to build out the entire 17 acre campus over time the company announced

November 20, 2007: RxElite Announces 3d Quarter Financials Conference Call
RxElite will hold a conference call to review its financial results for the third quarter ended September 30, 2007, on Tuesday, November 27, 2007, at 2:00 p.m. EST the company announced

November 8, 2007: RxElite Board of Directors Approves Name and Trading Symbol Change
The RxElite Board of Directors approved the Company to change its name and trading symbol to RxElite, Inc. As of November 7, 2007, RxElite, Inc. is trading under the symbol RXEI on the OTC bulletin board.

October 25, 2007: RxElite to Present at Rodman & Renshaw Healthcare Conference
RxElite Holdings, Inc., a wholly-owned operating subsidiary of Southridge Technology Group, Inc. (OTC Bulletin Board: SOUT - News) and a developer, manufacturer, and marketer of specialty generic prescription drug products, announced today that it will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference in New York on November 5 -7, 2007

October 24, 2007: CORRECTION - RxElite Files Registration Statement with Securities and Exchange Commission
RxElite corrected an earlier press release entitled, "RxElite Files Registration Statement with Securities and Exchange Commission" issued on Friday, October 12, 6:29 pm ET. The statement referring to the registration statement should have read, "According to the registration rights agreement entered into in connection with the private placement, we are obligated to cause this registration statement to be declared effective by the SEC on or before April 8, 2008."

October 18, 2007: RxElite Appoints New Chairman and CEO; Management Positions for Continued Growth
RxElite appointed Peter Williams to be Chairman of the Board, while the Company's founder and President, Jonathan Houssian, was appointed Chief Executive Officer, and Earl Sullivan was appointed Chief Operating Officer the company announced today

October 12, 2007: RxElite Files Registration Statement with Securities and Exchange Commission
RxElite announced the filing of their Registration Statement with the Security and Exchange Commission for sale of shares from their recent round of financing.

October 12, 2007: Oppenheimer report - Company Update

August 31, 2007: Money Week reference to RxElite

August 21, 2007: RxElite named one of Entrepreneur Magazine's hot 500 fastest growing business

July 23, 2007: Southridge Technology Group, Inc. Common Shares to Commence Trading as SOUT.OB & Announces Closing of $19.6 Million Financing

June 28, 2007: Oppenheimer report - Company Update

June 15, 2007: RxElite and Zach System S.p.A. sign joint venture product development agreement
RxElite Holdings, Inc (Meridian, ID) and Zach System S.p.A. (Milan, Italy), a fine chemical manufacturer and a member company of Zambon Group S.p.A, have announced a joint venture product development agreement. The collaboration will focus on developing generic sterile ophthalmic products for regulated markets and will leverage RxElite's experience in generic drug manufacturing and distribution and Zach System's expertise in developing and manufacturing active pharmaceutical ingredients.

May 31, 2007: Oppenheimer report - Company Update

May 16, 2007: Oppenheimer report - Quarterly Update

May 2, 2007: RxElite announces launch of generic Sevoflurane
RxElite announced that MINRAD International, Inc. received approval from the U.S. Food and Drug Administration to market Sojourn» (Sevoflurane) inhalation anesthetic in the United States. RxElite is Minrad's exclusive marketing and distribution partner for Sojourn» (Sevoflurane) for the United States market.

January 31, 2007: RxElite Appoints Patrick Poisson to Position of Vice President - RxElite Holdings, Inc announces the appointment of Patrick Poisson to the position of Vice President, Sterile Products where he will oversee the manufacture and development of products in RxElite's sterile product portfolio.

This Web site is subject to RxElite.com Terms of Use